<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201396</url>
  </required_header>
  <id_info>
    <org_study_id>T1303</org_study_id>
    <nct_id>NCT00201396</nct_id>
  </id_info>
  <brief_title>A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <brief_summary>
    <textblock>
      Investigate the effect of induction MEPFL chemotherapy followed by concurrent&#xD;
      chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with&#xD;
      advanced NPC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale of induction chemotherapy:&#xD;
&#xD;
      Distant metastasis is the major cause of treatment failure and deaths in patients with&#xD;
      loco-regionally advanced NPC.&#xD;
&#xD;
      Concurrent chemoradiotherapy may prolong survivals for patients with advanced NPC, but it is&#xD;
      still flawed by high incidence of distant metastasis.&#xD;
&#xD;
      Induction chemotherapy with MEPFL has been shown to reduce the incidence of distant&#xD;
      metastasis in a Phase II study.&#xD;
&#xD;
      Induction chemotherapy plus concurrent chemoradiotherapy may improve the survival of patients&#xD;
      with advanced NPC.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Investigate the effect of induction MEPFL chemotherapy followed by concurrent&#xD;
      chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with&#xD;
      advanced NPC.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This is a randomized, multi-center Phase III study. Patients will be randomized to CCRT with&#xD;
      or without the MEPFL induction chemotherapy.&#xD;
&#xD;
      Type and number of patients:&#xD;
&#xD;
      Patients with stage IVA (T4) and/or IVB (N3) but without distant metastasis will be enrolled.&#xD;
      A total of up to 480 patients will be randomized to detect an improvement of median overall&#xD;
      survival from 5.8 to 8.7 years, with an a=0.05 and power of 0.8 using a two-sided logrank&#xD;
      test with one interim analysis.&#xD;
&#xD;
      Treatment schedule:&#xD;
&#xD;
      Induction chemotherapy and CCRT:&#xD;
&#xD;
      Arm A: Weekly cisplatin concurrently with radiotherapy Arm B: Induction MEPFL three cycles&#xD;
      followed with weekly cisplatin concurrently with radiotherapy.&#xD;
&#xD;
      Study endpoints:&#xD;
&#xD;
      The primary endpoint is the disease-free survival that will be calculated as the duration&#xD;
      between the date of randomization and the date of recurrence of NPC at any site including&#xD;
      persistent disease after +induction chemotherapy/CCRT, or death from any cause (failed), or&#xD;
      the date of withdrawal (last contact date, censored), or the scheduled data analysis date&#xD;
      (censored).( revised 8/27/2004)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the disease-free survival.</measure>
    <time_frame>10 years</time_frame>
    <description>follow up for 2 years after off study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints include overall survival and tumor response rate.</measure>
    <time_frame>10 years</time_frame>
    <description>follow up for 2 years after off study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>A arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction/CCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CCRT</intervention_name>
    <description>Radiation with weekly Cisplatin</description>
    <arm_group_label>A arm</arm_group_label>
    <arm_group_label>B arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin</intervention_name>
    <description>Induction C/T + CCRT</description>
    <arm_group_label>B arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proved nasopharyngeal carcinoma.&#xD;
&#xD;
          -  T4NxM0 or TxN3M0 disease by UICC/AJCC 1997 staging system. (30)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status &lt; 2.&#xD;
&#xD;
          -  A leukocyte count ≥3750/mL, Hb ≥ 10 g/dL, and a platelet count ≥100,000/mL.&#xD;
&#xD;
          -  A serum bilirubin level &lt; 1.5 mg/dL, serum creatinine level &lt; 1.6 mg/dL or creatinine&#xD;
             clearance &gt; 60 mL/min.&#xD;
&#xD;
          -  Age less than 70 years old&#xD;
&#xD;
          -  An informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of metastatic disease.&#xD;
&#xD;
          -  Presence of another malignancy other than treated squamous/basal cell carcinoma of the&#xD;
             skin.&#xD;
&#xD;
          -  Presence of uncontrolled hypertension, poorly controlled heart failure.&#xD;
&#xD;
          -  Presence of active infection.&#xD;
&#xD;
          -  Patients who have been or are being treated with chemotherapy, radiotherapy,&#xD;
             immunotherapy, or other experimental therapies.&#xD;
&#xD;
          -  Women who test positive for pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruey-Long Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taiwan cooperative oncology group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>115</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital(Lin-Kou),</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://english.nhri.org.tw/inst_cancer/ca_TCOGresearch.php</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A Multicenter Phase III Trial</keyword>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <keyword>Stage IV Nasopharyngeal Carcinoma (NPC)</keyword>
  <keyword>randomization</keyword>
  <keyword>disease-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

